1. Home
  2. CYN vs PLUR Comparison

CYN vs PLUR Comparison

Compare CYN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cyngn Inc.

CYN

Cyngn Inc.

HOLD

Current Price

$1.23

Market Cap

22.9M

Sector

Technology

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$2.11

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYN
PLUR
Founded
2013
2001
Country
United States
Israel
Employees
62
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9M
25.5M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
CYN
PLUR
Price
$1.23
$2.11
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
197.7K
10.9K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
$368,138.00
$1,336,000.00
Revenue This Year
$3,359.28
$97.38
Revenue Next Year
$347.47
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$1.22
$2.22
52 Week High
$41.54
$5.96

Technical Indicators

Market Signals
Indicator
CYN
PLUR
Relative Strength Index (RSI) 39.76 29.08
Support Level N/A N/A
Resistance Level $1.76 $2.58
Average True Range (ATR) 0.08 0.13
MACD -0.00 0.01
Stochastic Oscillator 27.54 0.00

Price Performance

Historical Comparison
CYN
PLUR

About CYN Cyngn Inc.

Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: